297 reports of this reaction
1.6% of all SEVELAMER CARBONATE reports
#12 most reported adverse reaction
NEPHROGENIC ANAEMIA is the #12 most commonly reported adverse reaction for SEVELAMER CARBONATE, manufactured by Genzyme Corporation. There are 297 FDA adverse event reports linking SEVELAMER CARBONATE to NEPHROGENIC ANAEMIA. This represents approximately 1.6% of all 19,097 adverse event reports for this drug.
Patients taking SEVELAMER CARBONATE who experience nephrogenic anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROGENIC ANAEMIA is a less commonly reported adverse event for SEVELAMER CARBONATE, but still significant enough to appear in the safety profile.
In addition to nephrogenic anaemia, the following adverse reactions have been reported for SEVELAMER CARBONATE:
The following drugs have also been linked to nephrogenic anaemia in FDA adverse event reports:
NEPHROGENIC ANAEMIA has been reported as an adverse event in 297 FDA reports for SEVELAMER CARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROGENIC ANAEMIA accounts for approximately 1.6% of all adverse event reports for SEVELAMER CARBONATE, making it a notable side effect.
If you experience nephrogenic anaemia while taking SEVELAMER CARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.